• Refine Query
  • Source
  • Publication year
  • to
  • Language
  • 16
  • 14
  • 4
  • 4
  • 2
  • 1
  • Tagged with
  • 47
  • 47
  • 47
  • 26
  • 21
  • 17
  • 15
  • 14
  • 14
  • 12
  • 12
  • 11
  • 10
  • 10
  • 9
  • About
  • The Global ETD Search service is a free service for researchers to find electronic theses and dissertations. This service is provided by the Networked Digital Library of Theses and Dissertations.
    Our metadata is collected from universities around the world. If you manage a university/consortium/country archive and want to be added, details can be found on the NDLTD website.
1

VIRAL MODULATION OF MHC CLASS II-MEDIATED ANTIGEN PRESENTATION

Wang, Nan 24 June 2009 (has links)
Indiana University-Purdue University Indianapolis (IUPUI) / Vaccinia virus (VV) has been used as a vaccine, yet safety concerns remain due to its viral immunoevasive properties. Among these, VV infection of antigen presentation cells (APC) perturbs MHC class II-mediated antigen (Ag) presentation. The goals of this project include: 1) to define mechanisms by which VV disrupts class II presentation; and 2) to examine whether disruption of the class II pathway by VV alters T cell responses in vitro and in vivo. A significant reduction in the expression of the class II chaperone, invariant chain (Ii), was observed during the late stage of VV infection. Yet surface expression of MHC class II molecules was maintained along with cell viability. To examine whether VV acts solely to disrupt host protein synthesis, B cells were treated with an inhibitor of translation-cycloheximide (CHX). Like VV, CHX negatively regulated Ii protein expression and class II presentation. Ii proteolysis also contributed in part to reduce Ii expression in VV infected and CHX treated APC. Yet only VV infection altered lysosomal protease expression, potentially influencing Ii degradation. Over-expression or ectopic-expression of Ii partially protected cells from VV-induced class II dysfunction. These studies suggest VV destabilizes class II molecules by disrupting Ii expression. To examine the presentation of viral Ags by class II, CD4 T cells from VV-primed mice were used. Viral proteins were presented by class II shortly after APC exposure to low concentrations of VV. The presentation of VV Ags correlated temporally with reductions in exogenous peptide presentation. At higher MOI (≥ 1), class II presentation of VV Ags was reduced. To examine the in vivo effects of VV on Ag presentation, a mouse model of ovalbumin-induced airway hypersensitivity was used. Th2 cytokine production was reduced, while a novel inflammatory cytokine Interleukin-17 (IL-17) production was enhanced in asthmatic VV-infected mice. In health mice, repeated VV infections lead to enhanced CD8 T cell production of Interferon-γ (IFN-γ) and IL-17. Finally, antibodies to a viral protein H3 were generated and shown to preserve class II presentation. Together these studies suggest VV disruption of the class II pathway may blunt T cell responses to VV.
2

Increased stability of class II MHC-peptide complexes in macrophages infected with <i>Mycobacterium avium</i> and the examination of a novel role for Cathepsin L in the innate immune response to <i>Francisella Novicida</i> infection

Florence, William C. 08 March 2007 (has links)
No description available.
3

Neutrophil responses to infection with leishmania parasites: MHC class II-expression and parasite life-stage interactions

Davis, Richard Elliot 01 December 2016 (has links)
The vector-borne protozoan Leishmania spp. cause the spectrum of disease known as leishmaniasis in human and animal hosts. The most common manifestations of leishmaniasis are the chronic, ulcerative skin disease cutaneous leishmaniasis (CL), and the more serious visceral leishmaniasis (VL) in which parasites take up residence in internal organs, causing death if not treated. The role of neutrophils (PMNs) in the immune response to CL and VL is unclear. It is s generally thought that PMNs are only a short-lived effector cell, and have been disregarded as playing a role in chronic Leishmania spp. infection. As both CL and VL are diseases characterized by increased inflammatory immune mediators, we hypothesized that PMNs from human or animal models of chronic leishmaniasis would display different properties from PMNs from healthy controls. We found in a subset of CL and VL patients circulating PMNs expressing HLA-DR, the human form of MHC class II, a molecule thought to be restricted primarily to professional antigen cells. When we examined PMNs recruited to CL skin lesions in human patients, or similar lesions in experimental murine model of CL, we found significantly increased MHC class II+ PMNs. Circulating HLA-DR+ PMNs also expressed the co-stimulatory molecules CD80, CD86 and CD40. While this suggested an antigen-presenting cell-like phenotype by these HLA-DR+ PMNs, compared to conventional HLA-DR- PMNs, HLA-DR+ PMNs showed not only a neutrophil-like appearance and function, but in fact increased activation, degranulation, intracellular MPO and phagocytosis of parasites and zymosan particles. Incubation of healthy control whole blood with inflammatory cytokines resulted in increased HLA-DR+ PMNs and the presence of hladrb1 mRNA, suggesting a connection between neutrophil “priming” and upregulation of HLA-DR. In addition to HLA-DR+ PMNs in CL patients, we also identified the presence of so-called “low-density” neutrophils (LD-PMNs). These neutrophils, which are enriched in low-density fractions following centrifugation of blood over a density gradient, are reported in numerous disease states, including cancer, HIV, and systemic lupus erythematosus. In some disease states, LD-PMN are reported to be immunosuppressive toward T cell activation and proliferation. However, LD-PMNs from leishmaniasis patients showed no evidence of immunosuppression. Additionally, we found that LD-PMNs show significantly increased surface expression of MHC class II, suggesting a heretofore unappreciated connection between these atypical neutrophil phenotypes. We also investigated the in vitro interactions with different Leishmania infantum life-stages, both those that cause acute infection (promastigotes) and amastigotes, which are found during chronic stages of the disease. We found that PMNs are readily infected by all L. infantum life-stages, but that amastigotes may have different methods of interacting with PMN surface receptors and are better equipped to avoid PMN anti-microbial responses. These data suggest that circulating PMNs in chronic leishmaniasis may have unique phenotypes and interact differently with the Leishmania spp. life-cycle present during chronic infection. Further investigation of the role of PMNs and atypical PMN phenotypes in chronic disease may help identify new immunomodulatory roles for this cell type.
4

Cellular immune responses to allografts and cytomegalovirus /

Engstrand, Mats, January 2003 (has links)
Diss. (sammanfattning) Uppsala : Univ., 2003. / Härtill 5 uppsatser.
5

The importance of CTLA-4 and HLA class II for type 1 diabetes immunology /

Jonson, Carl-Oscar, January 2007 (has links) (PDF)
Diss. (sammanfattning) Linköping : Linköpings universitet, 2007. / Härtill 4 uppsatser.
6

Antigen and superantigen presentation as defined by the MHCII-accessory proteins and associated-peptides

Fortin, Jean-Simon 05 1900 (has links)
MHCII molecules expose a weave of antigens, which send survival or activation signals to T lymphocytes. The ongoing process of peptide binding to the MHC class II groove implicates three accessory molecules: the invariant chain, DM and DO. The invariant chain folds and directs the MHCII molecules to the endosomal pathway. Then, DM exchanges the CLIP peptide, which is a remnant of the degraded invariant chain, for peptides of better affinity. Expressed in highly specialized antigen presenting cells, DO competes with MHCII molecules for DM binding and favors the presentation of receptor-internalized antigens. Altogether, these molecules exhibit potential immunomodulatory properties that can be exploited to increase the potency of peptide vaccines. DO requires DM for maturation and to exit the ER. Interestingly, it is possible to monitor this interaction through a conformation change on DOβ that is recognized by the Mags.DO5 monoclonal antibody. Using Mags.DO5, we showed that DM stabilizes the interactions between the DO α1 and β1 chains and that DM influences DO folding in the ER. Thus, the Mags.DO5+ conformation correlates with DO egress from the ER. To further evaluate this conformation change, directed evolution was applied to DO. Of the 41 unique mutants obtained, 25% were localized at the DM-DO binding interface and 12% are at the solvent-exposed β1 domain, which is thought to be the Mags.DO5 epitope. In addition, I used the library to test the ability of HLA-DO to inhibit HLA-DM and sorted for the amount of CLIP. Interestingly, most of the mutants showed a decrease inhibitory effect, supporting the notion that the intrinsic instability of DO is a required for its function. Finally, these results support the model in which DO competes against classical MHCII molecules by sequestering DM chaperone’s function. MHCII molecules are also characterized by their ability to present superantigens, a group of bacterial or viral toxins that coerces MHCII-TCR binding in a less promiscuous fashion than what is observed in a canonical setting. While the mechanism of how bacterial superantigens form trimeric complexes with TCR and MHCII is well understood, the mouse mammary tumor virus superantigens (vSAG) are poorly defined. In the absence of a crystal structure, I chose a functional approach to examine the relation between vSAG, MHCII and TCR with the goal of uncovering the overall trimolecular architecture. I showed that TCR concomitantly binds both the MHCII α chain and the vSAG and that TCR-MHCII docking is almost canonical when coerced by vSAGs. Because many peptides may be tolerated in the MHCII groove, the pressure exerted by vSAG seems to tweak conventional TCR-MHCII interactions. Furthermore, my results demonstrate that vSAG binding to MHCII molecules is conformation-dependent and abrogated by the CLIP amino-terminal residues extending outside the peptide-binding groove. In addition, they also suggest that vSAGs cross-link adjacent MHCIIs and activate T cells via a TGXY motif. / Les molécules du CMH présentent une panoplie d'antigènes qui, lorsque reconnus par un lymphocyte T spécifique, indique à ce dernier de survivre ou de s'activer. Le processus menant à la liaison d'un peptide à la poche du CMH de classe II, implique trois molécules accessoires, soit la chaine invariante, DM et DO. La chaine invariante replie et dirige les molécules du CMHII jusqu'à la voie endosomale. Ensuite, DM échange CLIP, peptide découlant de la dégradation de la chaine invariante, pour d'autres ayant une meilleure affinité. Exprimé seulement chez certaines cellules présentatrices, DO compétitionne avec les molécules du CMHII pour la liaison à DM et ainsi favorise la présentation d'antigènes internalisés par des récepteurs membranaires. Ensemble, ces protéines ont un potentiel immunomodulatoire pouvant être exploité afin d'augmenter l'efficacité de vaccin peptidique. DO requiert DM pour arriver à maturité et sortir du RE. Cette interaction, qui induit un changement de conformation dans la chaine β de DO, peut être sondée à l'aide de l'anticorps monoclonal Mags.DO5. En utilisant cet anticorps, nous avons montré que DM stabilise l'interaction entre les domaines α1 et β1 de DO et influence son repliement dans le RE. Donc, la conformation qui révèle l’épitope Mags.DO5 corrèle avec la migration de DO hors du RE. Afin d'étudier plus précisément ce changement de conformation, DO fut contraint à une ronde d’évolution dirigée. Des 41 mutants obtenus, 25% se retrouvent à l'interface DO- DM et 12% se retrouvent à la surface exposée au solvant du domain β1, région hypothétique de l'épitope Mags.DO5. De plus, la bibliothèque de mutants a été testée pour son habileté à inhiber l'activité de DM. La plupart des mutants montre une activité inhibitrice diminuée, ce qui supporte le model où DO compétionne les molécules du CMHII en séquestrant le rôle chaperon de DM. Les molécules du CMHII ont l'unique habileté de présenter les superantigènes, une famille de toxines virales et bactériennes qui force l'interaction CMHII-TCR de façon beaucoup moins spécifique qu'en contexte canonique. Alors que la façon dont les superantigènes bactériens s'assemblent avec le CMHII et le TCR soit bien comprise, la nature du complexe trimoléculaire découlant des superantigènes du virus de la tumeur mammaire de la souris (vSAG) reste mal définie. En l'absence d'une structure cristalline, une approche fonctionnelle a été choisie pour examiner la relation des vSAGs avec le CMHII et le TCR avec le but de dévoiler l'architecture de ce multi-complexe protéique. Je montre que le TCR lie parallèlement la chaine α du CMHII et vSAG, ce qui résulte en une interaction presque canonique. Puisque différents peptides peuvent être tolérés lors de cet ancrage, il semble que vSAG ajuste les interactions CMHII-TCR conventionnelles. En outre, mes résultats montrent que vSAG reconnait un épitope conformationnel et que cette liaison peut être abrogée par l'extension amino-terminale du peptide CLIP, laquelle s'étend en deçà de la niche. Finalement, mes résultats suggèrent que vSAG peut réticuler plusieurs CMHII adjacents et active les cellules T via son motif TGXY.
7

Studium epigenetické regulace HLA genů II. třídy na úrovni histonových modifikací / The study of epigenetic regulation of HLA class II genes at the level of histone modification

Černoch, Marek January 2014 (has links)
Introduction: The epigenetic modifications can significantly affect and alter the gene activity by regulating their expression, having direct impact on various processes in human body. Epigenetic processes are involved in ethiopathogenesis of many diseases. From this point of view, MHC genes are very important as they were linked to many autoimmune disorders, for example type 1 diabetes mellitus. In general autoimmune diseases appear to be connected to certain MHC class II genes. Aims: The aim of this thesis is to determine the relationship between expression levels and histone modifications present in the promoter area of MHC class II gene, DQA1. Moreover, we also analyze and compare the DQA1 gene mRNA expression depending on the QAP promoter allele. Methods: We isolated both nucleic acids (DNA and RNA) and leukocytes from peripheral blood samples collected from voluntary donors. DNA was utilized for genotypization of individuals. RNA was subjected to reverse transcription and the quantitative PCR was performed in order to determine the level of expression. Leukocytes were used for chromatin immunoprecipitation, which was evaluated using quantitative PCR. Results: The expression level of QAP allele 3.1 was found to be higher than for the rest of the alleles Allele 4.1A showed, on the other hand,...
8

Caractérisation et suivi chez l’Homme des réponses lymphocytaires T CD4 périphériques spécifiques d’allergènes, naturelles ou induites lors de traitement par immunothérapie allergénique / Characterization and monitoring of human peripheral allergen-specific CD4 T cell responses in healthy and allergic individuals or during allergen-specific immunotherapy

Bonvalet, Mélodie 16 December 2011 (has links)
L’immunothérapie allergénique (ITA) est la seule thérapie capable d’agir sur l’étiologie des allergies. La compréhension des mécanismes d’action de ce traitement et la mise en évidence de biomarqueurs d’efficacité favoriserait l’optimisation de l’ITA. A l’aide des tétramères de classe II, nous avons suivi les lymphocytes T CD4 périphériques spécifiques d’allergènes, acteurs centraux de la réaction allergique, dans des conditions normales, pathologiques ou en cours d’ITA, afin d’établir un lien entre ces trois situations physiologiques. Nous avons mis en évidence des différences entre les réponses lymphocytaires T CD4 spécifiques d’allergènes saisonniers et perannuels, chez les individus sains et allergiques. Puis, lors de 2 études cliniques d’ITA sublinguale, l’une menée chez des adultes allergiques aux pollens de graminées traités pendant 4 mois et l’autre menée chez des enfants allergiques aux acariens traités pendant 1, nous avons respectivement observé une diminution des lymphocytes Th2A et une augmentation de la production d’IFN- γ liées au traitement. Toutefois, ces variations ne corrèlent pas avec l’efficacité clinique de l’ITA observée dans ces deux études. Les limites d’utilisation des tétramères de classe II nous ont amené à rechercher si l’expression de marqueurs d’activation membranaires pouvait remplacer un marquage « tétramère ». Alors qu’une corrélation insuffisante a été observée entre le marquage « tétramère » et l’expression des marqueurs d’activation testés, nous avons mis en évidence 3 populations cellulaires aux propriétés fonctionnelles diverses, soulignant l’hétérogénéité des réponses lymphocytaires spécifiques d’allergènes. De plus, la découverte des lymphocytes Th2A pourrait être une approche prometteuse pour le suivi des réponses lymphocytaires T CD4 spécifiques d’allergènes lors d’ITA à plus long terme. / Allergenic immunotherapy (AIT) is currently the only curative treatment for allergic disease. Whereas efficacy of this treatment is well established, its mechanisms of action are not clearly understood and predictive as well as surrogate biomarkers are needed to further support AIT development. We focused on allergen specific CD4 T cells, highly involved in allergic inflammation, and monitored their responses both in normal and pathologic conditions, or during AIT. Using MHC class II tetramers, we highlighted distinct patterns of polarization between seasonal and perennial allergen-specific CD4 T cells as well as between healthy and allergic individuals. Then, allergen-specific CD4 T cell responses were monitored during 2 double-blind placebo-controlled sublingual AIT clinical trials. After short term AIT (4 months), we observed a decrease of Th2A cells, a newly define subset, thought to contain most allergen-specific CD4+ T cells. IFN-γ production was increased after one year of treatment. However, these variations were not related to AIT clinical efficacy. We further compared the expression of various activation markers and MHC class II tetramer staining following in vitro stimulation in order to circumvent inherent limitation of tetramers. No correlation could be established between tetramer staining and the expression of multiple activation markers in allergen-stimulated CD4 T cells. Combining these methods helps understanding patient heterogeneity regarding CD4 T cell responses. Moreover, Th2A cells detection is likely a promising approach to identify allergen-specific CD4 T cell during long-term AIT.
9

Regulation of expression of the HLA class II gene, DQB1 /

Sukiennicki, Teresa Lyn. January 2000 (has links)
Thesis (Ph. D.)--University of Washington, 2000. / Vita. Includes bibliographical references (leaves 106-140).
10

The role of MARCH1 in the B16 melanoma model

de Montigny, Auriane 10 1900 (has links)
No description available.

Page generated in 0.0537 seconds